Catalyst Event
Amgen Inc (AMGN) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
6/8/2026, 12:00:00 AM
Reports emerge that The New England Journal of Medicine is investigating allegations of research misconduct in the pivotal study for the vasculitis drug Tavneos, following a prior FDA proposal to withdraw the drug from the market. This significant regulatory risk is expected to cause a major price impact.
Korean Translation
혈관염 치료제 타브네오스(Tavneos)의 주요 연구에 대한 연구 부정 행위 혐의를 뉴잉글랜드 저널 오브 메디슨(NEJM)이 조사 중이라는 보도가 나옴. 이는 이전에 미국 FDA가 해당 약물의 시장 철수를 제안한 데 이은 것으로, 중대한 규제 리스크에 따른 큰 폭의 주가 영향이 예상됨.
Related Recent Events
Kinder Morgan Inc. (KMI) · Other
James Holland, Chief Operating Officer, is set to retire, effective September 4, 2026. Ken Grubb, currently VP and Chief Project Officer, will succeed him as COO. The transition was announced on April 22, 2026. Impact is estimated at 1% due to the planned nature of the succession scheduled.
9/4/2026, 12:00:00 AM
HEICO Corp (HEI) · Earnings Release
Q3 2026 earnings release on 2026-08-24 scheduled.
8/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Q2 FY2027 earnings release scheduled; medium impact from financial updates expected.
8/20/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Q2 2026 earnings release on August 19, 2026, with analysts forecasting an EPS of approximately $2.21-$2.25; low impact estimated as the market typically prices in consensus expectations prior to the release expected.
8/19/2026, 12:00:00 AM
CoreWeave Inc (CRWV) · Earnings Release
Q2 2026 earnings release for August 18, 2026, is of high importance as such releases often cause >10% price impact; event scheduled.
8/18/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Earnings Release
Q2 2026 earnings release and conference call on August 18, 2026. Estimated price impact ~5% as earnings releases typically drive significant volatility; scheduled.
8/18/2026, 12:00:00 AM